Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 8Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × HhAntag691 × Clear all
NCT06616623 2026-02-27

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡